From radiobiology to technology: What is changing in radiotherapy for prostate cancer

Expert Review of Anticancer Therapy

Volumn 14, Issue 5, 2014, Pages 553-564

  De Bari, Berardino ^a   Fiorentino, Alba ^b   Arcangeli, Stefano ^c   Franco, Pierfrancesco ^d   D'Angelillo, Rolando Maria ^e   Alongi, Filippo ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c Radiotherapy Unit   (Italy)

^d Ospedale Regionale U Parini   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Outcome; prostate cancer; radiobiology; radiotherapy; technique; technology

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOTHERAPY EQUIPMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM DISEASE; REVIEW; SAFETY; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; MALE; PROCEDURES; PROSTATIC NEOPLASMS; RADIOTHERAPY;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 84898988757     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.883282     Document Type: Review

References (88)

1. NCCN. Available from: www.nccn.org/professionals/physician-gls/pdf/ prostate.pdf
2. Heidenreich A, Bellmunt J, Bolla M, et al. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71
3. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59(4):572-83
4. Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012;24(7):461-73
5. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241-9
6. Staffurth J. Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010;22(8):643-57
7. Mitchell JM. Urologists' use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med 2013; 369(17):1629-37
8. Fogarty GB, Ng D, Liu G, et al. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy-a comparison among prostate cancer patients treated in an Australian centre. Radiat Oncol 2011;6(1): 108
9. Rong Y, Tang G, Welsh JS, et al. Helical tomotherapy versus single-arc intensitymodulated arc therapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys 2011;81(1):284-96
10. Davidson MT, Blake SJ, Batchelar DL, et al. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys 2011;80(5): 1550-8
11. Davidson MT, Blake SJ, Batchelar DL, et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009;93(2):168-73
12. Udrescu C, De Bari B, Rouvière O, et al. Does hormone therapy modify the position of the gold markers in the prostate during irradiation A daily evaluation with kV-images. Cancer Radiother 2013;17(3): 215-20
13. Udrescu C, Jalade P, de Bari B, et al. Evaluation of the respiratory prostate motion with four-dimensional computed tomography scan acquisitions using three implanted markers. Radiother Oncol 2012; 103(2):266-9
14. Magrini SM, Bertoni F, Vavassori V, et al. Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including. 1759 patients treated during two decades (1980-1998. Int J Radiat Oncol Biol Phys 2002;52(5):1310-19
15. Pegurri L, Buglione M, Girelli G, et al. Changes in patterns of practice for prostate cancer radiotherapy in Italy. 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society (AIRO). Tumori 2013; In press
16. Steel GG. Basic clinical radiobiology. Arnold; London, UK: 2003
17. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52(1):6-13
18. Fowler J, Chappel R, Ritter M. Is alpha/beta for prostate tumors really low Int J Radiat Oncol Biol Phys 2001;50: 1021-31
19. Arcangeli S, Scorsetti M, Along F. Will. SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer A review. Crit Rev Oncol Hematol 2012;84:101-8
20. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007;68:24-33
21. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials Clin Oncol 2007;19(5): 289-301
22. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: a/b = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):e17-24
23. Proust-Lima C, Taylor JM, Sécher S, et al. Confirmation of a low a/b ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011;79(1):195-201
24. Pedicini P, Caivano R, Strigari L, et al. In regard to Miralbell et al. Int J Radiat Oncol Biol Phys 2013;85(1):10-11
25. Pedicini P. In regard to pedicini et al. Int J Radiat Oncol Biol Phys 2013;87(5):858
26. Pollack AW, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013;31(31):3860-8
27. Alongi F, Di Muzio N. Image-guided radiation therapy: a new era for the radiation oncologist Int J Clin Oncol 2009; 14(6):568-9
28. Zaorsky NG, Harrison AS, Trabulsi EJ, et al. Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol 2013;10(10):565-79
29. Hartford AC, Galvin JM, Beyer DC, et al. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for Intensity-modulated Radiation Therapy (IMRT). Am J Clin Oncol 2012;35(6): 612-17
30. Bauman G, Rumble RB, Chen J, et al. Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012;24(7):461-73
31. Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:125-9
32. Munoz F, Fiandra C, Franco P, et al. Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med 2012;117: 1057-70
33. Udrescu C, De Bari B, Rouvière O, et al. Does hormone therapy modify the position of the gold markers in the prostate during irradiation A daily evaluation with kV-images. Cancer Radiother 2013;17(3): 215-20
34. Zaorsky NG, Studenski MT, Dicker AP, et al. Stereotactic body radiation therapy for prostate cancer: is technology ready to be the standard of care Cancer Treat Rev 2013;39:212-18
35. De Bari B, Fiorentino A, Greto D, et al. Prostate cancer as a paradigm of multidisciplinary approach Highlights from the Italian young radiation oncologist meeting. Tumori 2013;99:637-49
36. Alongi F, De Bari B, Franco P, et al. The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med 2013;118(4):660-78
37. De Bari B, Alongi F, Franco P, et al. The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II)-A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med 2013;118(7):1220-39
38. Lukka H, Hayter C, Julian JA, et al. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132-8
39. Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of Phase III randomized trial. Int J Radiat Oncol Biol Phys 2011;81:1271-8
40. Kuban DA, Nogueras-Gonzalez NG, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010;78(Suppl):S58
41. Arcangeli G, Saracino B, Gomellini S, et al. A prospective Phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78(1):11-18
42. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and pattern of failures in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172-8
43. Higgins GS, McLaren DB, Kerr GR, et al. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:982-9
44. Kuban D, Tucker S, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70(1):67-74
45. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from MRC RT01 randomised controlled trial. Lancet Oncol 2007;8: 475-87
46. Al-Magmani AA, Heemsbergen WD, Levendag PC, Lebesque JV. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose-escalation trial. Radiother Oncol 2012;96:13-18
47. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastasis-free survival. Int J Radiat Oncol Biol Phys 2008;71:1028-33
48. Kuban D, Pollack A, Huang E, et al. Hazard of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1260-8
49. Dearnaley D, Syndicus I, Sumo G, et al. Conventional versus hypofractionated high dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from CHHiP randomized controlled trial. Lancet Oncol 2012;13:4354
50. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010;10:1
51. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011;6:3
52. McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional Phase 1 feasibility trial. Cancer 2011;118(15):3681-90
53. Fuller DB, Shirazi R, Naitoh J, et al. Virtual HDR SBRT. For localized prostatic carcinoma: efficacy and quality of life assessment. Int J Radiat Oncol Biol Phys 2011;81:S423-4
54. Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011;97:43-8
55. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):877-82
56. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105
57. Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J Clin Oncol 2011;29:2020-6
58. Loblaw A, Cheung P, D'Alimonte L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013;107(2):153-8
59. Lukka HR. A Randomized Phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer-RTOG CCOP Study; 201125. Katz AJ Personal communication American Society Therapeutic Radiation Oncology annual meeting; 2012
60. Zamboglou N, Tselis N, Baltas D, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013;85:672-8
61. Tselis N, Tunn UW, Chatzikonstantinou G, et al. High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol 2013;8:115
62. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41
63. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366: 572-8
64. Thompson IM Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35
65. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30
66. Kruser TJ, Jarrard DF, Graf AK, et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 2011;117:2629-36
67. Cozzarini C, Fiorino C, Di Muzio N, et al. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study. Radiother Oncol 2008;88:26-33
68. Massaccesi M, Cilla S, Deodato F, et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a Phase II trial. Anticancer Res 2013;33(6):2785-9
69. Alongi F, De Bari B, Campostrini F, et al. Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 2013;88(3):550-63
70. Wallner KE, Nori D, Morse MJ, et al. 125iodine reimplantation for locally progressive prostatic carcinoma. J Urol 1990;144:704-6
71. Loening SA, Turner JW. Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate 1993;23:283-90
72. Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective Phase 2 study. Cancer 2007;110(7):1485-92
73. Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat 2003;2:339-44
74. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999;54(5):880-3
75. Wong WW, Buskirk SJ, Schild SE, et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006;176(5):2020-4
76. Moman MR, van der Poel HG, Battermann JJ, et al. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 2010;9(2): 119-25
77. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;77(5): 1338-44
78. Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10
79. Hsu CC, Hsu H, Pickett B, et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial ppi for prostate cancer. Int J Radiat Oncol Biol Phys 2013;85(2):370-7
80. Jo Y, Fujii T, Hara R, et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy-preliminary results. BJU Int 2012;109(6):835-9
81. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67:1106-12
82. Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013;86(2):324-9
83. Ramey SJ, Marshall DT. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol 2013; 31(6):1339-45
84. Kalapurakal JA, Mittal BB, Sathiaseelan V. Re-irradiation and external hypertheramia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report. Br J Radiol 2001;74: 745-51
85. Ricchetti F, Barra S, Agostinelli S, et al. Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. Tumori 2011;97:492-7
86. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007;84:197-215
87. Vavassori A, Jereczek-Fossa BA, Beltramo G, et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 2010;96:71-5
88. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys 2012;82: 889-97